A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Inclusion Criteria: * Adult patient, \>/= 18 years of age * Chronic Hepatitis C of \>/= 6 months duration at screening * HCV genotype 1 and quantifiable HCV RNA at screening (Roche COBAS TaqMan HCV test) * Naïve for treatment with interferon (pegylated or non-pegylated) * Body Mass Index (BMI) 18-35 inclusive, minimum weight 45 kg * Females of child-bearing potential and males with female partners of childbearing potential must use 2 forms of effective non-hormonal contraception Exclusion Criteria: * Pregnant or lactating women and males with female partners who are pregnant or lactating * Decompensated liver disease or impaired liver function * Cirrhosis or incomplete/transition to cirrhosis * Non-hepatitis C chronic liver disease * Hepatitis B or HIV infection * History of neoplastic disease within the last 5 years, except for localized or in situ carcinoma of the skin * History of pre-existing renal disease (except for nephrolithiasis) or severe cardiac disease * History of drug or alcohol abuse within the last year or alcohol consumption of \> 2 units per day; cannabinoid use is excepted